Quest Diagnostics has completed its acquisition of select clinical testing assets from Spectra Laboratories, owned by Fresenius Medical Care. The deal positions Quest to provide dialysis-related clinical testing to independent dialysis clinics previously served by Spectra. Under a separate laboratory services agreement, Quest will begin providing comprehensive dialysis-related laboratory services for Fresenius Medical Care's U.S. dialysis centers, serving approximately 200,000 patients annually. The service transition will start this month and is expected to complete by early 2026.
In a social media landscape shaped by hashtags, algorithms, and viral posts, nurse leaders must decide: Will they let the narrative spiral, or can they adapt and join the conversation?
...
